New ointment shows promise for rare skin scaling disease

NCT ID NCT04154293

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested two strengths of a topical isotretinoin ointment (TMB-001) in 34 people aged 9 and older with congenital ichthyosis, a rare genetic skin condition causing severe scaling. The main goal was to see if the ointment could reduce scaling by at least 50% compared to a placebo ointment. The trial is now complete, and results will show whether this treatment is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Topical isotretinoin (TMB-001) ointment
What this could lead to
If successful, this could provide a new topical treatment to reduce severe scaling and improve skin appearance in people with congenital ichthyosis.
What could go wrong
This is a small Phase 2 trial with only 34 participants, so results may not apply to everyone. Topical isotretinoin can cause skin irritation, and the treatment may not work for all subtypes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOSOMAL RECESSIVE CONGENITAL ICHTHYOSIS-LAMELLAR ICHTHYOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Austin Institute for Clinical Research, Inc

    Metairie, Louisiana, 70005, United States

  • Cincinnati Children's Hospital

    Cincinnati, Ohio, 45229, United States

  • Medical Dermatology Specialists

    Phoenix, Arizona, 85006, United States

  • Minnesota Clinical Study Center

    New Brighton, Minnesota, 55112, United States

  • Murdoch Children's Research Institute, RCH

    Melbourne, Victoria, 3052, Australia

  • Premier Specialists, The church

    Kogarah, Sydney, NSW 2217, Australia

  • Queensland Children's Hospital

    Brisbane, Queensland, 4101, Australia

  • Stanford University School of Medicine

    Palo Alto, California, 94304, United States

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19140, United States

  • The Indiana Clinical Trials Center

    Plainfield, Indiana, 46168, United States

  • Yale Center for Clinical Investigation

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.